From the Guidelines
Platelet-Derived Growth Factor (PDGF) Releasing Nanofractions (PDRN) injection is not recommended for routine use in dermatology due to lack of firm evidence supporting its effectiveness. The current evidence does not support the use of PDRN injections in dermatology, as most studies have methodological problems or failed to show a significant effect on healing [ 1 ].
Key Points to Consider
- The use of platelet-derived growth factors has been of interest as a therapeutic target, but the earliest studies were limited by poor design and high dropout rates [ 1 ].
- Recombinant platelet-derived growth factor has been assessed in six RCTs, but these studies either showed no improvement in healing or were marred by significant methodological problems [ 1 ].
- Other recombinant growth factors, such as basic fibroblast growth factor, epidermal growth factor, and vascular endothelial growth factor, have also been studied, but the evidence is not strong enough to support their use in routine care [ 1 ].
Clinical Implications
Given the lack of firm evidence supporting the effectiveness of PDRN injections in dermatology, it is recommended to prioritize established treatments with a stronger evidence base. However, it is essential to note that PDRN injections may still be considered in specific cases where other treatments have failed, and patients should be fully informed of the potential risks and benefits.
Treatment Alternatives
Established treatments for dermatological conditions, such as topical creams, oral medications, and lifestyle modifications, should be considered as first-line options. In cases where these treatments are ineffective, alternative therapies, such as laser treatments or chemical peels, may be considered under the guidance of a qualified medical professional.
From the Research
Effect of Platelet-Derived Growth Factor (PDGF) Releasing Nanofractions (PDRN) Injection in Dermatology
- PDRN has been shown to possess tissue repairing, anti-ischemic, and anti-inflammatory properties, making it a potential treatment option in regenerative medicine and dermatology 2.
- The mechanism of action of PDRN is thought to be related to the engagement of adenosine A2A receptors, as well as the provision of nucleosides and nucleotides for the "salvage pathway" 2.
- In the context of dermatology, PDRN has been compared to other filler products, such as hyaluronic acid, in terms of its efficacy and safety for periocular rejuvenation 3.
- Studies have shown that PDRN filler injection can improve skin elasticity, hydration, and roughness, with a higher improvement rate compared to hyaluronic acid filler injection in some cases 3.
- However, it is worth noting that the current evidence is limited, and more studies are needed to fully understand the effects of PDRN injection in dermatology.
- Other treatments, such as platelet-rich plasma (PRP) injections, have also been shown to be effective in improving skin firmness and elasticity, although the relationship between PRP and PDRN is not fully understood 4.
- Additionally, combination treatments, such as chemical peels with botulinum toxin injections and dermal fillers, have been shown to be effective in achieving synergistic beneficial effects in facial skin rejuvenation 5.
- The use of nanocarrier-based transdermal delivery systems has also been explored as a potential method for enhancing skin penetration and improving the efficacy of dermatological treatments 6.